



Lay the foundations for a healthy and happy family



VISTA™ Carrier Screening

- 1200+ Panel, 1200+ Diseases Detected in 1 Test

Helping parents to detect genetic risks, provide reproductive guidance, and prevent birth defects.



Specimen Requirement

2-5 mL peripheral blood



Turnaround Time

27 working days



Target Population

All couples who are planning a pregnancy or during early pregnancy, including those:

- With normal phenotypes and no family history of monogenic diseases.
- Who wants to have a healthy baby using assisted reproductive technology (ART).
- Who are close blood relatives.



Advantages

- Reasonable disease selection
- Large database of mutations following ACMG guidelines
- Extensive experience in genetic disease screening and research
- Complete lab qualifications and quality certifications
- Genetic counseling expert team and online search tools



Detection Time

- Before or during early pregnancy.
- In early pregnancy, it is recommended that both parents be detected.



Technology

Target area capture - high-throughput sequencing technology

Characteristics

Rigorous: Inclusion of prenatal and early pregnancy diseases with clear pathogenic genes and severe and early onset diseases, following requirements of international guidelines.

Comprehensive: Detection of exon regions, splicing regions, some intron regions, promoter regions and UTR regions containing 1200+ target genes.

Accurate: Applying strict performance evaluation and quality control standards; pathogenicity of sites determined in strict accordance with ACMG guidelines.

Highly efficient: Screening of 1200+ autosomal recessive and X-linked single-gene diseases in 1 test, improving the comprehensive prevention and control of birth defects.

Testing Content

VISTA™ Carrier Screening screens for more than 1200 genes associated with 1200+ recessive monogenic diseases.

Classification	Diseases
Inherited Metabolic Disorders	Wilson Disease; Primary Carnitine Deficiency; Phenylketonuria; Hyperphenylalaninemia, BH4-deficient, A; MUT-Related Methylmalonic Acidemia; Methylmalonic Aciduria and Homocystinuria cblC type, 2,4-Dienoyl-CoA Reductase Deficiency, 2-Methylbutyryl Glycinuria, 3-beta-Hydroxysteroid Dehydrogenase Deficiency, etc.
Neuromuscular Skeletal Related Disorders	Duchenne Muscular Dystrophy; Spinal Muscular Atrophy; Joubert Syndrome 2; Joubert Syndrome 3, Ullrich congenital muscular dystrophy 1, Spinal muscular atrophy, X-linked 2, infantile, etc.
Cutaneous Disorders	Oculocutaneous Albinism Type 1; Autosomal Recessive Congenital Ichthyosis 1; Autosomal Recessive Congenital Ichthyosis 4A; Autosomal Recessive Congenital Ichthyosis 4B; Sjögren-Larsson syndrome, X-Linked Dyskeratosis Congenita, Epidermolytic hyperkeratosis, etc.
Circulatory System Disorders	Hemophilia B; Alpha-thalassemia; Beta-thalassemia; Sickle Cell Anemia, Methemoglobinemia Due to Deficiency of Methemoglobin Reductase, Thiamine-Responsive Megaloblastic Anemia Syndrome, etc.
Endocrine Issues and Autoimmune Disorders	Hemophagocytic lymphohistiocytosis, familial, Severe combined immunodeficiency, B cell-negative; X-Linked Severe Combined Immunodeficiency, Congenital Adrenal Hyperplasia due to 11-beta-Hydroxylase-Deficiency, DCLRE1C-Related Severe Combined Immunodeficiency, Common Variable Immune Deficiency 8 with Autoimmunity, etc.
Gastrointestinal and Urinary System Disorders	Progressive Familial Intrahepatic Cholestasis 2; Alport syndrome 2, autosomal recessive; Nephrotic syndrome, type 1, Polycystic Kidney Disease 4 with or without Polycystic Liver Disease, etc.
The Respiratory and Otorhinolaryngology System Disorders	Cystic Fibrosis; Autosomal Recessive Deafness 1A; Autosomal Recessive Deafness 4, with Enlarged Vestibular Aqueduct, Congenital Cataracts, Hearing Loss, And Neurodegeneration, etc.
Complex Multisystem Disorders	Meckel Syndrome 2, X-Linked Hypohidrotic Ectodermal Dysplasia; COACH syndrome, etc.

www.bgi.com/global/
info@bgi.com



For a complete listing of our global offices, please visit www.bgi.com/global/.

Copyright ©2023 BGI. All rights reserved. The BGI logo and VISTA logo are trademarks of BGI. All trademarks are the property of BGI, or their respective owners. Information, descriptions and specifications in this publication are subject to change without notice.

Published October 2023.

Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please contact a representative for regional availability. The company reserves the right of final interpretation.



@BGI Genomics